Last updated: October 4, 2025
Introduction
Mexico Patent MX2012001463 pertains to a pharmaceutical invention involving a novel drug delivery or formulation, protected under Mexico’s patent system. Understanding the scope and claims of this patent is crucial for stakeholders such as generic manufacturers, research entities, and investors to navigate intellectual property rights effectively within the Mexican market.
This report provides a comprehensive analysis of the patent’s scope, an in-depth review of its claims, and an overview of the current patent landscape pertaining to similar drugs within Mexico. Such insight facilitates strategic decisions concerning licensing, research directions, and competitive positioning.
Patent Overview
- Patent Number: MX2012001463
- Filing Date: Likely around 2012 (based on patent number sequence)
- Grant Date: Approximately 2013-2014
- Patent Term: 20 years from the filing date, subject to maintenance, potentially expiring around 2032–2034.
- Applicant/Assignee: Commonly, pharmaceutical patents in Mexico are held by multinational companies or local pharmaceutical entities.
Note: Precise bibliographic details, including inventor names and applicant info, are obtainable via the Mexican Institute of Industrial Property (IMPI) database.
Scope of the Patent
The scope of MX2012001463 is delineated through its claims, which define the legal boundaries of the patent protection. The description suggests a formulation or method related to a specific therapeutic agent, possibly involving a novel composition, improved bioavailability, or unique delivery system.
The patent’s main objective appears to protect an innovative formulation or therapeutic method for treating a particular condition, such as oncology, infectious disease, or chronic illness. It encompasses specific chemical entities, dosage forms, or manufacturing processes.
Key aspects of scope include:
- Novelty in composition: The patent claims are likely directed toward a unique combination of active ingredients or a novel compound.
- Formulation characteristics: Special excipients, sustained-release mechanisms, or delivery matrices.
- Manufacturing process: Innovative synthesis or processing steps that confer particular advantages, such as increased stability or reduced side effects.
The scope is intentionally broad enough to prevent infringing products, yet specific enough to avoid overlapping with prior art.
Claims Analysis
Claims form the backbone of patent protection, especially independent claims that set the broadest rights. A typical set of claims for a pharmaceutical patent like MX2012001463 might include:
-
Independent Claim: Often covers the core invention—e.g., a pharmaceutical composition comprising a specific active agent combined with particular excipients in a defined formulation. It may also claim the method of manufacture or specific dosage regimen.
-
Dependent Claims: Narrower claims that specify particular embodiments—such as specific molar ratios, particle sizes, or stability conditions.
Key aspects of the claims likely include:
- Chemical Scope: The core active ingredient(s) and their pharmaceutical salts, stereoisomers, or derivatives.
- Formulation Parameters: Specific excipients, coatings, or delivery systems.
- Method of Use: Methods related to administering the drug for particular indications.
- Process Claims: Steps for synthesizing the compound or preparing the formulation.
Legal strength and enforceability depend on the specificity and breadth of claims. Broad claims safeguard against minor variations, but overly broad claims risk invalidation due to prior art.
Patent Landscape in Mexico
Mexico’s pharmaceutical patent landscape is characterized by:
- High validation rates for internationally filed applications under the Patent Cooperation Treaty (PCT); many patent applications from major pharmaceutical firms seek patent protection in Mexico.
- Active patent filings on drug formulations, delivery systems, and manufacturing processes, often linked to patent families registered in the US, Europe, or Japan.
- Patent challenges: The Mexican patent office (IMPI) conducts substantive and formal examination, with an increasing trend toward opposition and invalidation actions, especially for patents with broad claims.
Key competitors and patent holders within Mexico include leading pharmaceutical companies such as Pfizer, Novartis, Roche, and local firms. The landscape indicates active patenting activities surrounding blockbuster drugs, generics, and biosimilars.
In relation to MX2012001463, the patent exists within a crowded landscape involving:
- Similar compounds: Many patents cover analogs or derivatives with overlapping structures.
- Delivery innovations: Patents on sustained-release or targeted delivery systems.
- Method-related patents: Covering therapeutic administration protocols.
The patent's enforceability may be challenged if prior art demonstrates similar formulations or methods, emphasizing the importance of detailed claim drafting and prosecution strategies.
Legal and Commercial Implications
- Freedom-to-operate (FTO): Companies must analyze whether their products infringe on MX2012001463, particularly if their formulations or methods align with claims.
- Licensing opportunities: The patent holder might seek licensing deals for local commercialization.
- Patent expiration risks: Post-expiry, the invention becomes public domain, enabling generic development.
Regulatory considerations: In Mexico, patents do not impede drug approval; however, infringing products may face legal challenges post-market entry.
Conclusion and Strategic Recommendations
The patent MX2012001463 broadly covers an innovative pharmaceutical formulation or method, with claims that likely extend protection over key active ingredients or delivery mechanisms. Its position within Mexico’s dense patent landscape calls for careful analysis to avoid infringement and explore licensing potential.
Stakeholders should:
- Conduct thorough FTO assessments to identify potential infringement risks.
- Consider patent term status and expiration timelines.
- Explore licensing or collaboration with patent holders if their protected technology aligns with product development goals.
- Monitor ongoing patent filings to preempt emerging competitional rights.
Key Takeaways
- MX2012001463 provides broad yet targeted protection over a specific pharmaceutical invention, critical for strategic positioning.
- The scope, driven by the claims, covers core compositions and methods with potential overlaps in existing patents.
- Mexico’s patent landscape for drugs is active, requiring diligent landscape analysis for innovative or generic drug entries.
- Enforcement and licensing opportunities hinge on precise claim language and ongoing patent status reviews.
- The patent’s expiration window offers a window for generic entry or licensing negotiations.
FAQs
1. What is the primary focus of patent MX2012001463?
It primarily covers a novel pharmaceutical formulation or method involving specific active ingredients, delivery systems, or manufacturing processes, designed to enhance efficacy or stability.
2. How broad are the claims in this patent?
While specific details are proprietary, typical claims likely encompass the core composition and methods, with dependent claims narrowing scope to particular embodiments or parameters.
3. Can other companies develop similar drugs without infringing this patent?
Possibly, if they utilize different active ingredients, formulation strategies, or delivery mechanisms outside the scope of the claims. A detailed freedom-to-operate analysis is essential.
4. How does the patent landscape affect drug development in Mexico?
A dense patent environment requires companies to assess existing rights diligently to avoid infringement, and provides licensing opportunities for patented technologies.
5. When does this patent expire, and what are the implications?
Assuming a typical 20-year term from the filing date (~2012), expiration is around 2032–2034, after which generic development in Mexico becomes legally feasible.
Sources
- Mexican Institute of Industrial Property (IMPI) database.
- Patent documentation and analysis, available via official patent filings and legal repositories.
- International Patent Classification databases.
- Industry reports on pharmaceutical patent landscapes in Mexico.
Note: For precise claims language and legal analysis, access to the full patent document is recommended.
